Delving into the Latest Updates on Apixaban with Synapse

The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are:
* To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement.
* To identify the optimal length of anticoagulation in the treatment of LV Thrombus
After randomisation participants will:
* Continue their prescribed oral anticoagulant for the remainder of the trial
* Discontinue their prescribed oral anticoagulant for the remainder of the trial

Start Date01 Dec 2026

Sponsor / Collaborator

Queen Mary University of London

CTIS2024-515630-33-00

/ Not yet recruitingPhase 3IIT

A single dose of apixaban for the prevention of thrombotic events in the context of long-distance flights (DANCE FLIGHT)

Start Date30 Nov 2026

Sponsor / Collaborator-

CTIS2024-518861-90-00

/ Not yet recruitingPhase 4IIT

Thromboprophylaxis with apixaban during neoadjuvant therapy for muscle-invasive bladder cancer (ACB): An international randomized controlled trial evaluating apixaban versus no anticoagulation in patients scheduled to undergo radical cystectomy or chemoradiotherapy for muscle-invasive bladder cancer

Start Date01 Sep 2026

Sponsor / Collaborator-

100 Clinical Results associated with Apixaban

Login to view more data

100 Translational Medicine associated with Apixaban

Login to view more data

100 Patents (Medical) associated with Apixaban

Login to view more data

6,387

Literatures (Medical) associated with Apixaban

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Plain language summary examining clinical event related costs associated with changing medication from apixaban to rivaroxaban in people with non-valvular atrial fibrillation in the USA and Germany

Article

Author: Dworatzek, Elke ; Duan, Cecilia ; Kongnakorn, Thitima ; Zhang, Michelle ; Hines, Dionne M. ; Subash, Rupesh ; Kisser, Agnes

31 Dec 2026·RENAL FAILURE

Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis

Review

Author: Liu, Xin ; Meng, Jie ; Zhou, Yilun ; Wu, Xiaoyuan ; Yang, Yu ; Sheng, Dacheng

This study aimed to evaluate the comparative efficacy and safety of apixaban and rivaroxaban versus vitamin K antagonists (VKAs) in anticoagulation management in a dialysis population. PubMed, Embase, and the Cochrane Library were searched for studies comparing apixaban or rivaroxaban with VKAs in patients with atrial fibrillation (AF) undergoing dialysis. The primary efficacy endpoints included stroke/systemic embolism (SSE) and all-cause mortality. Safety outcomes encompassed major bleeding, intracranial hemorrhage, and gastrointestinal bleeding. Risk ratios (RR) with 95% confidence intervals (CI) were synthesized using random-effects models. The meta-analysis included three randomized controlled trials (RCTs) and eight observational studies. Pooled analyses showed that apixaban and rivaroxaban were associated with lower risks of major bleeding (RR 0.57, 95% CI: 0.51-0.63), gastrointestinal bleeding (RR 0.66, 95% CI: 0.57-0.76), and intracranial hemorrhage (RR 0.54, 95% CI: 0.36-0.83) compared with VKAs. Additionally, apixaban and rivaroxaban were associated with reduced risk of SSE (RR 0.57, 95% CI: 0.46-0.72) and all-cause mortality (RR 0.73, 95% CI:0.63-0.83), although substantial heterogeneity was present. Exploratory dose-stratified analyses suggested both standard- and low-dose apixaban regimens were associated with favorable efficacy and hemostatic safety relative to warfarin. Consistent numerical trends were observed in the RCT-only analysis, though none reached statistical significance owing to limited sample size. In conclusion, apixaban and rivaroxaban are associated with lower risks of bleeding compared with VKAs in patients with AF and ESRD. However, evidence regarding their efficacy in preventing SSE, all-cause mortality and the optimal apixaban dosing regimen remains inconclusive and requires validation in large, dedicated RCTs.

01 Dec 2026·JOURNAL OF MOLECULAR MEDICINE-JMM

Measuring Neural Factor X Pathway Activity in Rodent Glioma Cell Culture and Brain Slices

Article

Author: Schiller, Maya ; Shavit-Stein, Efrat ; Golderman, Valery ; Chapman, Joab ; Gofrit, Shany Guly

Coagulation factor X (FX) plays a significant role in neuroinflammation and is considered a promising target for therapeutic intervention. However, because activated FX (FXa) levels in neural tissues are expected to be significantly lower than in plasma, a more sensitive, direct, and specific method is required for accurate detection. To measure FXa activity with high sensitivity, we used a fluorogenic substrate in combination with a panel of specific inhibitors to prevent nonspecific protease activity that potentially cleaves the substrate, initially validated in human normal and FX-deficient plasma. This approach allowed selective quantification of FXa activity in neural samples. To further characterize the FX pathway, we applied a FXa inhibitor (apixaban), a FX activator (Russell's viper venom X, RVVX), and commercially available FX and FXa to mouse brain slices and to glioma cell lines derived from human, rat, and mouse. FXa activity significantly increased following RVVX application in human plasma and mouse brain and was inhibited in a calcium-dependent manner in human plasma. In the mouse brain, apixaban inhibited only the FXa activity secreted from the slice rather than the slice-associated activity. In glioma cell lines, RVVX application increased cell-bound FXa activity, which was not inhibited by apixaban, while the activity secreted into the medium was elevated and inhibited by apixaban. Exposure to lipopolysaccharide reduced RVVX-induced FXa activity while increasing the thrombin activity in glioma cell lines from mice and rats, respectively. We developed a specific method of measuring basal FXa activity and induced from FX by RVVX, in plasma and secreted from brain slices and astrocyte tumor cells. The results were obtained in tissue with defined experimental conditions, pharmacologically differentiated tools, and biological validation as assessed by thrombin activity measurement. FXa activity in neural tissue is tightly regulated and undetectable without an FX activator. KEY MESSAGES: We developed a sensitive method using fluorescence substrate to measure the fine changes in FXa activity in neural tissue. Brain slice associated FXa activity differs from secreted activity in its response to activators and inhibitors, suggesting the complexity of FXa activity regulation in neural tissue. Specific set of conditions is needed to detect FXa activity in neural tissue.

348

News (Medical) associated with Apixaban

30 Jul 2026

·firstwordpharma.com

BMS pushes key readouts for Cobenfy, milvexian to 2027

Bristol Myers Squibb said Thursday it is lifting its financial outlook for the year, boosted by sales of its Eliquis anticoagulant alongside a strong showing from its newer drug lineup as well. Those figures helped fuel a 6% increase in second-quarter sales to nearly $13 billion, surpassing analyst expectations of $11.8 billion. The upbeat financial outlook came as BMS revealed that two of its closely watched pipeline catalysts face delays. The company now expects atrial fibrillation data from the Phase III LIBREXIA-AF1 trial of milvexian, an experimental oral factor XIa inhibitor seen as key to replacing eventual revenue declines from Eliquis, in the first quarter of 2027. It was originally due to read out late this year. The new timeline reflects a slower-than-expected accumulation of clinical events in the event-driven study. Delayed, but encouraged "As a reminder, [LIBREXIA-AF1] is being monitored by an independent data monitoring committee, which continues to endorse the study, and with the passage of time as the study progresses, we are increasingly encouraged about milvexian," CEO Chris Boerner said on an earnings call with analysts. Chief Medical Officer Christian Massacesi suggested the delay increases his confidence that milvexian can achieve both the primary endpoint of non-inferior efficacy to Eliquis and secondary endpoint of superior bleeding outcomes. Concerns over bleeding remain the biggest barrier to broader anticoagulant use, leaving around 40% of eligible atrial fibrillation patients undertreated, according to Chief Commercialisation Officer Adam Lenkowsky. He says milvexian may be able to address patients at higher bleeding risk, such as the elderly or those with renal impairment, and eventually "shift first-line decision making over time." From a sales standpoint, Eliquis remained the standout performer in the second quarter, with sales jumping 22% to $4.5 billion, with BMS increasing its full-year growth outlook for the factor Xa inhibitor to between 20%-25%, from 10%-15% guided in April. Lenkowsky said Eliquis' share of new US prescriptions is approaching 80%.ADEPT timeline shifts Meanwhile, topline data readouts from the ADEPT programme evaluating BMS's schizophrenia treatment Cobenfy in Alzheimer's disease psychosis have also been pushed back to early 2027, from a previous target of later this year. Boerner said the shift was "based on the pace of enrolment in the ADEPT-2 and -4 studies and relapse events accruing more slowly than projected in ADEPT-1." In December, BMS said it was adding new patients to ADEPT-2 after "irregularities" were uncovered at some study centres. Nevertheless, the company plans on sharing two other pieces of data from the Cobenfy programme later this year: namely, safety and efficacy findings from the open-label lead-in portion of ADEPT-1, as well as data from ADEPT-3, a rollover study that lets patients who finished ADEPT-1, -2 and -4 continue on the drug. Cobenfy generated $63 million in quarterly sales, which is up 81% year over year. Elsewhere, BMS posted double-digit gains for several other products in its growth portfolio, including Reblozyl (+29%, $735 million), Breyanzi (+41%, $484 million), Camzyos (+60%, $416 million), Opdualag (+23%, $349 million) and Krazati (+14%, $55 million). Its immunotherapy Opdivo slipped 3% to $2.5 billion, though its subcutaneous formulation, Opdivo Qvantig, more than tripled to $261 million. Revlimid sales fell 49% to $425 million amid ongoing generic erosion. BMS now anticipates revenues in the range of $49 billion to $50 billion from $46 billion to $47.5 billion previously. Adjusted 2026 earnings are seen between $6.75 to $7.00 a share, up from its prior view of $6.05 to $6.35.

Financial StatementPhase 3

20 Jul 2026

·www.prnewswire.com

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

PRINCETON, N.J., July 20, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2026 financial results and recent business highlights after the market close on Thursday, August 6, 2026. CytoSorbents' management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30PM ET the same day. Conference Call and Webcast Details: Date: Thursday, August 6, 2026 Time: 4:30 PM ET Live webcast link: It is recommended that participants dial in approximately 10 minutes prior to the start of the call. An archived recording of the conference call will be available under the Investor Relations section of the Company's website at About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine storm and cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorbents' lead product, CytoSorb ®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb® was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb® has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb® is not yet approved or cleared in the United States. In the U.S. and Canada, CytoSorbents is developing the DrugSorb®-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb®, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb®, ContrastSorb, and others. For more information, please visit the Company's website at and follow us on Facebook and X and LinkedIn. Forward-Looking Statements This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, the impact of geopolitical events including the recent war in Iran, our ability to successfully obtain U.S. FDA and Health Canada regulatory approval and marketing authorization, our ability to complete our strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve operating cash-flow break-even in the second half of 2026, our ability to appropriately finance the Company, including our ability to meet our financial obligations and comply with the covenants under our existing debt agreement,, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 30, 2026, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. Please Click to Follow Us on Facebook and X U.S. Company Contact: Peter J. Mariani, Chief Financial Officer 305 College Road East Princeton, NJ 08540 [email protected] SOURCE Cytosorbents Corp 21% more press release views with Request a Demo

Drug ApprovalBreakthrough TherapyFinancial Statement

01 Jun 2026

·www.biospace.com

Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)

FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoagulant, Xarelto ® . Rivaroxaban is a direct oral anticoagulant prescribed to treat and prevent deep vein thrombosis and pulmonary embolism. It is also widely utilized to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The global market for Rivaroxaban is estimated to reach $12.7 Billion in 2026 and is set to expand to approximately $30.5 Billion by 2035, growing at a CAGR of 10.19% during the forecast from 2026 to 2035, ( Business Research Insights ). According to IQVIA Pharmafocus 2028 , the Canadian pharmaceutical market accounts for approximately 2.1% of the global pharmaceutical market and ranks as the 6th largest worldwide. Sunshine Biopharma has established a robust distribution network across Canada through its wholly owned Canadian subsidiary, Nora Pharma Inc. The addition of Rivaroxaban to our portfolio of drugs represents a strategic expansion for the Company in the area of anticoagulants. The Company's first generic anticoagulant, Apixaban (brand name Eliquis ® ) has been on the market for over three years. It is anticipated that Sunshine Biopharma's Rivaroxaban will be ready to ship to pharmacies in October 2026. "We are pleased to introduce Rivaroxaban oral tablets as the newest addition to our expanding portfolio of high-quality generic drugs," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This approval strengthens our position in the generics market and reflects our ongoing commitment to delivering affordable medicines that patients and healthcare providers can rely on." About Sunshine Biopharma Inc. Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: . All registered trademarks are the property of their respective owners. Safe Harbor Forward-Looking Statements This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings. For more information, please contact: Camille Sebaaly, CFO Direct Line: 514-814-0464 camille.sebaaly@sunshinebiopharma.com SOURCE : Sunshine Biopharma Inc. View the original press release on ACCESS Newswire

Drug Approval

100 Deals associated with Apixaban

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03213	Apixaban	B01AF02	DB06605

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Recurrent deep vein thrombosis	European Union	Accord Healthcare SL	23 Jul 2020
Recurrent deep vein thrombosis	Iceland	Accord Healthcare SL	23 Jul 2020
Recurrent deep vein thrombosis	Liechtenstein	Accord Healthcare SL	23 Jul 2020
Recurrent deep vein thrombosis	Norway	Accord Healthcare SL	23 Jul 2020
Thrombosis	China	Bristol-Myers Squibb/Pfizer EEIG	22 Jan 2013
Ischemic stroke	Japan	Bristol-Myers Squibb KK	25 Dec 2012
Systemic embolism	Australia	Bristol Myers Squibb Co.	21 Jul 2011
Atrial Fibrillation	European Union	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Atrial Fibrillation	Iceland	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Atrial Fibrillation	Liechtenstein	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Atrial Fibrillation	Norway	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Embolism	European Union	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Embolism	Iceland	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Embolism	Liechtenstein	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Embolism	Norway	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Ischemic Attack, Transient	European Union	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Ischemic Attack, Transient	Iceland	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Ischemic Attack, Transient	Liechtenstein	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Ischemic Attack, Transient	Norway	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011
Pulmonary Embolism	European Union	Bristol-Myers Squibb/Pfizer EEIG	18 May 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Limb-Threatening Ischemia	Phase 3	Brazil	Wyeth AB	09 Jan 2020
Limb injury	Phase 3	Brazil	Wyeth AB	09 Jan 2020
Cognitive Dysfunction	Phase 3	United States	Pfizer Inc.	19 Dec 2018
Cognitive Dysfunction	Phase 3	United States	Bristol Myers Squibb Co.	19 Dec 2018
Neoplasms	Phase 3	Austria	Bristol Myers Squibb Co.	11 Oct 2018
Neoplasms	Phase 3	Belgium	Bristol Myers Squibb Co.	11 Oct 2018
Neoplasms	Phase 3	Canada	Bristol Myers Squibb Co.	11 Oct 2018
Neoplasms	Phase 3	France	Bristol Myers Squibb Co.	11 Oct 2018
Neoplasms	Phase 3	Greece	Bristol Myers Squibb Co.	11 Oct 2018
Neoplasms	Phase 3	Italy	Bristol Myers Squibb Co.	11 Oct 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02464969 (Pubmed \| Lancet Haematol)	Phase 4	Venous Thromboembolism	229	Apixaban	rucbtikpjs(xwyxxwwrav) = rugdqoovts ajghrpankx (ojmtubrwnt ) View more	Positive	01 Jul 2026
				Standard of care	rucbtikpjs(xwyxxwwrav) = mdtukrousu ajghrpankx (ojmtubrwnt )
NCT03266783 (COBRRA, CTgov)	Phase 4	Hemorrhage \| Venous Thromboembolism	2,760	Apixaban (Apixaban Group)	vtqwribmpm = jsprrvwxdf lqziqffygd (lrofmzecdz, bbzdeungsf - atowegouki) View more	-	24 Jun 2026
				rivaroxaban (Rivaroxaban Group)	vtqwribmpm = xqmtwxcvqg lqziqffygd (lrofmzecdz, vgfsxkucnf - rrmqnuvgig) View more
ADA2026	Not Applicable	Atrial Fibrillation	369,480	Reduced-Dose Direct Oral Anticoagulants	ojajtmfblm(mskpvborwu): HR = 1.13, P-Value = 0.04	Positive	20 Jun 2026
				Standard-Dose Direct Oral Anticoagulants
ASCO2026	Not Applicable	Venous Thromboembolism hemoglobin \| thrombocytopenia \| CKD ... View more	11,380	Apixaban 5 mg	zcxfdbrmbw(uyuqofcilw) = haivhbpike mibhmpipxj (nntamgxocj ) View more	Similar	29 May 2026
				Rivaroxaban 20 mg	zcxfdbrmbw(uyuqofcilw) = lnmswqrlob mibhmpipxj (nntamgxocj ) View more
EHA2026	Not Applicable	Atrial Fibrillation \| Venous Thromboembolism	200	Apixaban 5 mg twice daily	cngnghnzst(woklrdredp) = fisiwxgvjp jklmsliiak (omgwthxupz ) View more	Positive	12 May 2026
				reduced DOAC doses	cngnghnzst(woklrdredp) = jutorhhhjq jklmsliiak (omgwthxupz ) View more
NCT03181386 (Pubmed \| Oral Surg Oral Med Oral Pathol Oral Radiol)	Phase 3	Atrial Fibrillation	58	Dabigatran or Apixaban	wuhrsesmdl(eggsmvdscd) = wlizbviqba aqlotjxtyq (fkxnueczol )	Positive	01 Apr 2026
				Warfarin	wuhrsesmdl(eggsmvdscd) = luinhdmwhx aqlotjxtyq (fkxnueczol )
NCT03266783 (COBRRA, Pubmed \| N Engl J Med)	Phase 4	Venous Thromboembolism	2,760	Apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily	txcwayqwpu(ksyslhcqbk) = yzymtethfn vazbuodpbf (agwyaptgfp ) View more	Positive	12 Mar 2026
				Rivaroxaban 15 mg twice daily for 21 days followed by 20 mg daily	txcwayqwpu(ksyslhcqbk) = xndhjdytlp vazbuodpbf (agwyaptgfp ) View more
ESGO2026	Not Applicable	Neoplasms	4	Apixaban	druqaqslym(onbdqwmlmm): OR = 0.33 (95.0% CI, 0.09 - 1.2), P-Value = 0.09 View more	Positive	28 Feb 2026
				Enoxaparin
NCT03192215 (ARCADIA, Pubmed \| Heart)	Phase 3	Cryptogenic Ischemic Stroke	881	Apixaban	ysehnxnmfo(grtblugwvd): HR = 0.72 (95.0% CI, 0.54 - 0.95) View more	Positive	20 Feb 2026
				Aspirin
ASCO_GI2026	Not Applicable	Venous Thromboembolism	2,526	Apixaban	derqlhwsxy(nvkoufxxhn): HR = 0.92 (95.0% CI, 0.81 - 1.06), P-Value = 0.257 View more	Positive	08 Jan 2026
				Rivaroxaban